Sanofi (NASDAQ:SNY) Shares Purchased by Transamerica Financial Advisors Inc.

Transamerica Financial Advisors Inc. raised its stake in shares of Sanofi (NASDAQ:SNY) by 20.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,747 shares of the company’s stock after acquiring an additional 987 shares during the quarter. Transamerica Financial Advisors Inc.’s holdings in Sanofi were worth $278,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in SNY. Intrust Bank NA grew its position in shares of Sanofi by 5.2% in the 4th quarter. Intrust Bank NA now owns 27,978 shares of the company’s stock worth $1,349,000 after acquiring an additional 1,391 shares in the last quarter. Orion Portfolio Solutions LLC boosted its holdings in Sanofi by 10.7% in the fourth quarter. Orion Portfolio Solutions LLC now owns 71,179 shares of the company’s stock worth $3,433,000 after purchasing an additional 6,893 shares during the period. Providence Capital Advisors LLC increased its stake in Sanofi by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock valued at $2,653,000 after purchasing an additional 201 shares during the last quarter. Easterly Investment Partners LLC raised its holdings in shares of Sanofi by 0.8% during the fourth quarter. Easterly Investment Partners LLC now owns 54,856 shares of the company’s stock worth $2,646,000 after purchasing an additional 446 shares during the period. Finally, Zions Bancorporation N.A. lifted its position in shares of Sanofi by 7.1% in the 4th quarter. Zions Bancorporation N.A. now owns 165,350 shares of the company’s stock worth $7,975,000 after buying an additional 10,990 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Performance

SNY opened at $55.82 on Friday. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $55.13 and its 200-day moving average is $52.79. The stock has a market cap of $141.66 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analyst Weigh In

SNY has been the subject of a number of recent research reports. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.